Bristol-Myers Squibb’s cardiovascular development leader discusses the importance of diversifying clinical trials for better patient outcomes.
Christen Harm
Advertisement
Christen Harm is Pharmaceutical Executive's Associate Editor. Email her at charm@mmhgroup.com
Articles by Christen Harm
Advertisement
Latest Updated Articles
Creating Medicines ‘Appropriate for All’Published: September 1st 2019 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Praxis Reports Positive Phase III Results for Ulixacaltamide in Essential Tremor
2
Setting the Limits of Autonomy with Autonomous Agents for Clinical Research
3
Eli Lilly’s Orforglipron Shows Superior Efficacy Across Multiple Phase III Trials in Type 2 Diabetes
4
Labels That Withstand Liquid Nitrogen
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
